Facing Your Company’s Sunshine Reporting, Best Price & Anti-Kickback Concerns Head On
Few would argue that “Value Based” deals between U.S. health manufacturers (device and pharmaceuticals, alike) are going to be a flash in the pan. The transformative changes underway for the past eight years in terms of drug and device underwriting and health care cost-management trends in our fragmented system have made these an imperative.
That said, there are a number of uncertainties regarding regulatory safe harbors that have not yet been framed for those of us supporting the manufacturer, payer, or provider client.
It is possible to make progress, however, by fostering efficient work processes, good documentation, and clear communications with CMS and contract partners.
Request a copy of our latest white paper today using the link above! Better yet, reach out to participate in a pilot project or develop a value statement today!